Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Compounding pharmacies stories

Nov 6, 2026

Eli Lilly strikes deal to sell obesity drugs directly on Hims & Hers platform

Eli Lilly announced a partnership allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform, sending Hims & Hers shares up more than 7%. The deal marks a significant course change for Hims, which had previously sold compounded GLP-1 knockoffs.

Nov 6, 2026·3 sources
00
Oct 30, 2026

FDA advisory committee reviews SYD-101 atropine eye drops for pediatric myopia

An FDA advisory committee convened on October 30 to discuss SYD-101, a low-dose atropine eye drop for slowing pediatric myopia that the FDA declined to approve last year. The treatment met its primary endpoint in a phase 3 trial, but the FDA determined the overall results were insufficient for approval.

Oct 30, 2026·1 source
00
Oct 28, 2026

HHS allows temporary compounding of six unapproved peptides

The Department of Health and Human Services announced a policy permitting compounding pharmacies to temporarily produce six peptides that have not yet been approved by FDA, advancing access to controversial wellness compounds while permanent regulations are developed.

Oct 28, 2026·5 sources
00
Oct 15, 2026

FDA finds black mold and contamination at Chinese factories making compounded GLP-1 drug components

US FDA inspectors documented egregious conditions at two Chinese factories producing key components for compounded semaglutide and tirzepatide drugs, including black mold on equipment, gross contamination on floors, and employees attempting to hide paperwork and dispose of products during inspections.

Oct 15, 2026·3 sources
00

FDA submits interim peptide access policy to White House for review

The Food and Drug Administration has submitted an interim access policy to the White House that would allow compounding pharmacies to temporarily produce and sell certain previously restricted peptides, a class of drugs favored by Health and Human Services Secretary Robert F. Kennedy Jr.

Oct 15, 2026·6 sources
00
Oct 7, 2026

Greenwich Rx recalls compounded glutathione nationwide due to elevated endotoxin levels

Greenwich Rx, a 503A compounding pharmacy in Tomball, Texas, is voluntarily recalling specific lots of its compounded glutathione to the consumer level due to potential elevated endotoxin levels. The FDA posted the company's announcement on October 1, 2026.

Oct 7, 2026·1 source
00
Aug 6, 2026

Texas Federal Court Dismisses Antitrust Lawsuit Against Eli Lilly and Novo Nordisk Filed by Compounding Pharmacy

A Texas federal judge has dismissed an antitrust lawsuit brought by compounding pharmacy Strive Specialties Inc. against pharmaceutical companies Eli Lilly and Novo Nordisk.

Aug 6, 2026·1 source
00

Top claims

  • ▪Novo Nordisk treatments available on Hims & Hers start at $149 per month for the Wegovy pill and $199 per month for the Wegovy injector pen
  • ▪Prior to the November 6, 2026 partnership, Hims & Hers patients had to leave the platform and navigate to LillyDirect to obtain Eli Lilly obesity drugs
  • ▪Leerink Partners analyst Michael Cherny described the November 6, 2026 agreement with Eli Lilly as a clear positive that completes Hims & Hers' effort to secure access to major GLP-1 drugmakers

People involved

Robert F. Kennedy Jr.

Subtopics

Drug Policy, Pricing & Approval2Antitrust litigation1BPC-1571Child health1Clinical trial endpoints1Drug development1Drug pricing1Eli Lilly1Epithalon1FDA drug approval1FDA regulation1Federal court rulings1Foundao1GLP-1 / Weight-Loss Medications1GLP-1 drugs1Government and Regulatory Policy1MOTS-c1Novo Nordisk1Obesity treatment1Ophthalmic topical1Peptide regulation1Peptide therapy1Peptide Therapy Safety1Peptides & Emerging Supplement Trends1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories